Advanced search
Publication Cover
International Medical Case Reports Journal Volume 17, 2024 - Issue
Submit an article Journal homepage
125
Views
0
CrossRef citations to date
0
Altmetric
Case reports

Trifluridine and Tipiracil Hydrochloride Combination-Induced Interstitial Pneumonia: A Case Report

Shun NakazawaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9414-1677
ORCID Icon,
Motoyasu KatoDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-3217-5118
ORCID Icon,
Yuriko TerayamaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
,
Naho Sakamoto MatubaraDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
,
Yoshihiko SatoDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
,
Ryoko MurashimaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
,
Daisuke HayakawaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
,
Shouichi OkamotoDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
&
Kazuhisa TakahashiDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-5749-4118
ORCID Icon show all
Pages 101-104 | Received 12 Oct 2023, Accepted 16 Jan 2024, Published online: 06 Feb 2024

References

  • Mayer RJ, Van Cutsem E, Falcone A, et al.; RECOURSE Study Group. Randomized trial of Tas-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–1919. doi:10.1056/NEJMoa1414325
  • Salvatore L, Rossini D, Moretto R, et al. Tas-102 for the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther. 2015;15(11):1283–1292. doi:10.1586/14737140.2015.1105746
  • Yoshino T, Mizunuma N, Yamazaki K, et al. Tas-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13(10):993–1001. doi:10.1016/S1470-2045(12)70345-5
  • Conti M, Bolzacchini E, Luchena G, et al. Tas-102 for refractory metastatic colorectal cancer: a multicenter retrospective cohort study. Cancers. 2023;15(13):3465. doi:10.3390/cancers15133465
  • List of serious adverse effects of Tas-102. Reporting period: march 24, 2014 (approval date) to August 31, 2019 [home page on the Internet]. Japan: TAIHO Phamaceutical Co., Ltd.; 2019. Available from: https://www.taiho.co.jp/medical/safety/files/pdf/728ecfd9b3c01399747f27473b4b4c92.pdf. Accessed April 20, 2023.
  • Kamei H, Ishibashi N, Tanigawa M, et al. Interstitial pneumonia in a patient treated with Tas-102 for metastatic colorectal cancer: a case report. J Med Case Rep. 2016;10(1):310. doi:10.1186/s13256-016-1097-y
  • Kono E, Hiramatsu M, Kobayashi T, et al. A case of interstitial pneumonitis induced by Tas-102 for liver and lung metastasis of colorectal cancer. Gan To Kagaku Ryoho. 2018;45(9):1365–1368. The data that support the findings of this study are available on request from the corresponding author.
  • Hasegawa Y, Ota T, Tsukuda H, et al. Drug-induced pneumonitis following the administration of Tas-102. Intern Med. 2016;55(19):2855–2859. doi:10.2169/internalmedicine.55.6629
  • Lind JS, Smit EF, Grünberg K, et al. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. J Thorac Oncol. 2008;3(9):1050–1053. doi:10.1097/JTO.0b013e318183a9f5
  • Distefano G, Fanzone L, Palermo M, et al. HRCT patterns of drug-induced interstitial lung diseases: a review. Diagnostics. 2020;10(4):244. doi:10.3390/diagnostics10040244
  • Nemery B, Bast A, Behr J, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J Suppl. 2001;32:30s–42s.
  • Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: a review of 196 case reports. Medicine. 2018;97(4):e9688. doi:10.1097/MD.0000000000009688
  • Ishiwata T, Ebata T, Iwasawa S, et al. Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP). Intern Med. 2017;56(17):2311–2315. doi:10.2169/internalmedicine.8271-16
  • Temmink OH, Emura T, de Bruin M, et al. Therapeutic potential of the dual-targeted Tas-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 2007;98(6):779–789. doi:10.1111/j.1349-7006.2007.00477.x
  • Thalambedu N, El-Habr AH. Gemcitabine induced pneumonitis: a case report and review of literature. J Community Hosp Intern Med Perspect. 2020;10(6):579–582. doi:10.1080/20009666.2020.1811071.
  • Barlési F, Villani P, Doddoli C, et al. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol. 2004;18:85–91. doi:10.1046/j.0767-3981.2003.00206.x

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.